A hierarchical classification management system based on the cardiology department's coronary heart disease drug library

Abstract

The hierarchical classification management system based on the cardiology coronary heart disease drug library specifically involves the technical field of drug hierarchical classification management. The solution includes a data collection and processing module, a hierarchical classification module, a data analysis module, and an analysis visualization module. The data collection and processing module classifies and collects the classified data of all drugs taken to treat coronary heart disease in the current period of time. The hierarchical classification module calculates and outputs the i-th drug efficacy evaluation value YWL of all drugs in turn. i , the i-th drug classification index DJ i , optimization adjustment coefficient DT of the i-th drug i The data analysis module calculates all drugs and outputs the optimization adjustment coefficient DT of the i-th drug i The present invention realizes real-time updating of side effects, comprehensive consideration of drug interactions and individual differences, and dynamic adjustment of classification and grading management by arranging the i-th drug with a low value below the median.

Description

Technical Field

[0001] The present invention relates to the technical field of drug classification and management, in particular to a classification and management system based on a cardiology department coronary heart disease drug library. Background Art

[0002] With the rapid development of information technology, the medical field is gradually realizing informatization and intelligence. In the treatment of coronary heart disease in cardiology, the selection and management of drugs are gradually relying on advanced computer systems and database technologies. In addition, the informatization and intelligent management system can greatly improve the efficiency and accuracy of drug treatment and provide doctors with more scientific and systematic medication recommendations.

[0003] In order to better manage the coronary heart disease drug library, it is also necessary to manage the drugs in a hierarchical and classified manner. The current existing technology has some problems and shortcomings in implementing this system. First, the relevant parameters of drug side effects are not updated in a timely and accurate manner, resulting in the calculation results of drug efficacy deviating from the actual situation. Second, the interactions between drugs and individual differences of patients are not fully considered, which leads to inaccurate classification levels. Finally, the calculations guiding the adjustment of the drug library lack unified adjustment management standards, which in turn affects the stability and reliability of the system.

[0004] Therefore, those skilled in the art provide a hierarchical classification management system based on the cardiology coronary heart disease drug library to solve the problems raised in the above background technology. Summary of the Invention

[0005] The technical problem solved by the present invention is to provide a hierarchical classification management system based on the cardiology coronary heart disease drug library to achieve real-time updating of side effects, comprehensive consideration of drug interactions and individual differences, and dynamic adjustment of classification and hierarchical management.

[0006] In order to solve the above problems, the present invention provides the following technical solutions:

[0007] The hierarchical classification management system based on the cardiology department's coronary heart disease drug library includes a data collection and processing module, a hierarchical classification module, a data analysis module, and an analysis visualization module. It features:

[0008] The data collection and processing module collects and classifies the classified data of all kinds of drugs used to treat coronary heart disease in the current period of time, and transmits the data to the grading and classification module;

[0009] The classification module calculates and outputs the i-th drug efficacy evaluation value YWL of all drugs in turn. i , the i-th drug classification index DJ i , optimization adjustment coefficient DT of the i-th drug i ;

[0010] The data analysis module calculates and outputs the optimal adjustment coefficient DT of the i-th drug for all drugs i Arrange them and optimize the hierarchical classification management of the i-th drug with a low value below the median;

[0011] The analysis visualization module displays the results of all drug arrangements and optimization adjustments;

[0012] The grading and classification module includes a unit for judging the efficacy of drugs, a unit for classifying drugs, and a unit for guiding the adjustment of drug libraries.

[0013] In calculating the efficacy evaluation value YWL of the i-th drug i This includes regular updates of data input on patient adverse reaction feedback over the current period.

[0014] Furthermore, the grading and classification module cooperates with the data collection and processing module to regularly update the side effects of all drugs to reflect the adverse reaction feedback of patients in the current period. This usually includes the following steps:

[0015] Data collection: Collect the number of adverse reactions F experienced by patients while taking the i-th drug, as well as the total number of people n who took the i-th drug in the current period;

[0016] Data analysis: Statistics were collected on the number of adverse reactions F and the total number of people n, and the FZ i =F / n calculation formula, calculate the incidence of all kinds of adverse drug reactions;

[0017] Index update: According to the analysis and calculation results, FZ i Updated to reflect current adverse reaction information.

[0018] Further: The calculation formula for the unit for judging the efficacy of the drug is as follows:

[0019] ;

[0020] in:

[0021] YWL i is the efficacy evaluation value of the i-th drug;

[0022] YF i is the content of the i-th drug component, YF i Reflects the content of the active ingredient used for therapeutic effects in the i-th drug;

[0023] J i is the dose of the i-th drug, J iReflects the recommended single-dose dosage of the i-th drug as marked on the medicine box;

[0024] JB i is the standard deviation of the dose of the i-th drug, JB i Reflects the degree of fluctuation of dose in actual quality;

[0025] FZ i is the side effect index of the i-th drug;

[0026] The dose of drug i in i Fixed, the standard deviation of the dose of drug i, JB i There are fluctuations, and It is a comprehensive consideration of the recommended dose and its fluctuation, so the square root calculation is the standard deviation of the dose of the i-th drug JB i After the fluctuation effect, the dose of the i-th drug J i and the weakening of.

[0027] Further: The calculation formula of the drug classification level division unit is as follows:

[0028] ;

[0029] in:

[0030] DJ i is the classification grade index of the i-th drug;

[0031] ZB i is the treatment cost of the i-th drug;

[0032] YWL max The maximum value for drug efficacy evaluation, YWL max Reflect all drugs for treating coronary heart disease in cardiology, calculate and output the efficacy evaluation value YWL of the i-th drug i The maximum value of

[0033] The result of the division represents the recommended dose required per unit of active ingredient, that is, the dosage efficiency of the drug.

[0034] Further: The calculation formula of the guiding drug library adjustment unit is as follows:

[0035] ;

[0036] T=(ZB avg / ZB i )×a;

[0037] in:

[0038] DT iOptimize the adjustment coefficient for the i-th drug;

[0039] YF avg is the average content of the drug component, YF avg Reflects the average content of ingredients in all drugs used to treat coronary heart disease in cardiology;

[0040] ZB avg is the average drug treatment cost, ZB avg Reflects the average cost of all drugs used to treat coronary heart disease in cardiology;

[0041] T is the adjustment factor, which is used to adjust the treatment cost to optimize the adjustment coefficient DT of the i-th drug i the impact of;

[0042] a is the adjustment coefficient, and its value range is {0.2-0.8}, which is calculated based on the last time all drugs are optimized for the adjustment coefficient DT of the i-th drug i , and arrange them in order of high and low to match the value range {0.2-0.8}:

[0043] The value of the i-th drug with a high ranking tends to be 0.8;

[0044] The value of the i-th drug with a low ranking tends to be 0.2.

[0045] Further: the guiding drug library adjustment unit optimizes the adjustment coefficient DT of the i-th drug of all drugs i The calculation output is performed and the values ​​are classified from left to right according to their height. Based on the setting that the low values ​​below the median need to be adjusted, the i-th drug is analyzed one by one. The specific analysis is as follows:

[0046] If the i-th drug is among all the drugs, its i-th drug efficacy evaluation value YWL i If the value is low, it means that the efficacy of the i-th drug is insufficient, and the composition and dosage of the i-th drug should be optimized and adjusted according to the dosage fluctuation and side effects;

[0047] If the i-th drug is among all the drugs, its i-th drug classification index DJ i If it remains at a low value for a long time, it means that the treatment cost of the drug is high and the efficacy is poor, and it is necessary to adjust the drug classification and find alternative drugs.

[0048] Further: the standard deviation JB of the i-th drug dosage i The calculation formula is as follows:

[0049] ;

[0050] ;

[0051] in:

[0052] J k is the drug dosage of the kth individual, J k Reflects the actual single dose of the i-th drug taken during the current period;

[0053] J avg is the average drug dose, J avg Reflects the average degree of single and actual dosage of the i-th drug taken by n patients in the current period.

[0054] Further: the content of the i-th drug component YF i The determination is carried out using analytical instruments such as high performance liquid chromatography, gas chromatography, and mass spectrometry. These devices can accurately measure the concentration of specific chemical components in the drug, thereby obtaining the content of the active ingredient. The specific implementation method is as follows:

[0055] Sample preparation: extracting the active ingredient from the i-th drug preparation, the extraction including the steps of dissolution, filtration, and concentration;

[0056] Instrumental analysis: The extracted and processed sample of the i-th drug preparation is injected into the analytical instrument and separated and detected using specific chromatographic and mass spectrometric conditions;

[0057] Data processing: Based on the signal output by the instrument, the content of the active ingredient is calculated by data processing software.

[0058] Further: the equipment used by the data collection and processing module includes a database management system and network equipment;

[0059] The equipment used in the grading and classification module includes computers, servers, and data processing software;

[0060] The equipment used by the data analysis module includes data analysis software;

[0061] The equipment used by the analysis and visualization module includes a display.

[0062] The effects of the above solution are as follows:

[0063] 1. The database management system of the present invention establishes a drug side effect database and realizes real-time docking with clinical data. It can timely update the drug side effect index FZ of the i-th drug by regularly collecting and analyzing the medication feedback and adverse reactions of patients in the current period. i , so as to ensure that the efficacy evaluation value of the i-th drug YWL i The calculation results are more accurate and reliable.

[0064] 2. The present invention uses the evaluation value YWL of the efficacy of the i-th drug i In the calculation of , the i-th drug dose J is introduced i and the standard deviation of the dose of the i-th drug JB i The differences in drug dosage recommendations and individual patient dosage fluctuations can be used to more comprehensively evaluate the efficacy and safety of drugs, which will help to more accurately determine the classification level of drugs and provide more scientific medication recommendations.

[0065] 3. The present invention optimizes the adjustment coefficient DT of the i-th drug according to the result of the guidance drug library adjustment unit i , can dynamically adjust and optimize the drug library, and for drugs with low median, if the i-th drug efficacy evaluation value YWL i If the long-term i-th drug classification index DJ is low, the efficacy can be optimized by adjusting the active ingredient content and recommended dose. i If the drug level is low, it is necessary to find alternative drugs. This cyclic optimization mechanism helps to continuously optimize the management of the drug library and improve the therapeutic effect and economy of drugs.

[0066] In addition, the results of all drug arrangements and optimization adjustments are displayed in graphical form, making it easy and intuitive to understand the status and trends of the drug library. At the same time, the system also provides intelligent decision-making support functions, providing personalized medication recommendations and management plans based on drug evaluation results and management needs. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 This is a flowchart of the method of this hierarchical classification management system;

[0068] Figure 2 This is a schematic diagram of the overall structural modules of this hierarchical classification management system;

[0069] Figure 3 This is a schematic diagram of the structure of the hierarchical classification management module in the present invention;

[0070] Figure 4 Optimize the adjustment coefficient DT for the i-th drug of all drugs in the present invention i Schematic diagram of the arrangement. DETAILED DESCRIPTION

[0071] The technical solutions in the embodiments of the present invention will be clearly and completely introduced below with reference to the accompanying drawings in the embodiments of the present invention.

[0072] For example 1, please refer to Figures 1-4 The hierarchical classification management system based on the cardiology department's coronary heart disease drug library includes a data collection and processing module, a hierarchical classification module, a data analysis module, and an analysis visualization module. It is characterized by:

[0073] The data collection and processing module collects and classifies the classified data of all kinds of drugs used to treat coronary heart disease in the current period of time and transmits them to the grading and classification module;

[0074] The classification module calculates and outputs the efficacy evaluation value YWL of the i-th drug of all drugs in turn i , the i-th drug classification index DJ i , optimization adjustment coefficient DT of the i-th drug i ;

[0075] The data analysis module calculates the optimal adjustment coefficient DT of the i-th drug output for all drugs i Arrange them and optimize the hierarchical classification management of the i-th drug with a low value below the median;

[0076] The analysis and visualization module displays the arrangement of all drugs and the results of optimization and adjustment;

[0077] Among them, the grading and classification module includes a unit for judging the efficacy of drugs, a unit for classifying drugs, and a unit for guiding the adjustment of the drug library;

[0078] In calculating the efficacy evaluation value YWL of the i-th drug i Including regular update data input of patient adverse reaction feedback over the current period;

[0079] The equipment used in the data collection and processing module includes database management system and network equipment;

[0080] The equipment used in the grading and classification module includes computers and servers, and data processing software;

[0081] The equipment used in the data analysis module includes data analysis software;

[0082] The equipment used in the analysis and visualization module includes a display.

[0083] This embodiment, through the coordination among modules, units, and devices, as well as the clear calculation purposes of the drug efficacy judgment unit, the drug classification and grading unit, and the drug library adjustment guidance unit, together constitute the core algorithm of the cardiology coronary heart disease drug library classification and management system. The design and application of these formulas help to make the selection of drugs more scientific and reasonable, and also provide strong support for the optimization and adjustment of the drug library.

[0084] See also Figure 1-4 The calculation formula for judging the drug efficacy unit is as follows:

[0085] ;

[0086] in:

[0087] YWL i is the efficacy evaluation value of the i-th drug;

[0088] YF i is the content of the i-th drug component, YF i Reflects the content of the active ingredient used for therapeutic effects in the i-th drug;

[0089] J i is the dose of the i-th drug, J i Reflects the recommended single-dose dosage of the i-th drug as marked on the medicine box;

[0090] JB i is the standard deviation of the dose of the i-th drug, JB i Reflects the degree of fluctuation of dose in actual quality;

[0091] FZ i is the side effect index of the i-th drug;

[0092] The dose of drug i in i Fixed, the standard deviation of the dose of drug i, JB i There are fluctuations, and It is a comprehensive consideration of the recommended dose and its fluctuation, so the square root calculation is the standard deviation of the dose of the i-th drug JB i After the fluctuation effect, the dose of the i-th drug J i and the weakening of;

[0093] The standard deviation of the dose of drug i JB i The calculation formula is as follows:

[0094] ;

[0095] ;

[0096] in:

[0097] J k is the drug dosage of the kth individual, J k Reflects the actual single dose of the i-th drug taken during the current period;

[0098] J avg is the average drug dose, J avg Reflects the average degree of single and actual dosage of drug i taken by n patients in the current period;

[0099] The content of the i-th drug component YF iThe determination is carried out using analytical instruments such as high performance liquid chromatography, gas chromatography, and mass spectrometry. These devices can accurately measure the concentration of specific chemical components in the drug, thereby obtaining the content of the active ingredient. The specific implementation method is as follows:

[0100] Sample preparation: extracting the active ingredient from the i-th drug preparation, the extraction including the steps of dissolution, filtration, and concentration;

[0101] Instrumental analysis: The extracted and processed sample of the i-th drug preparation is injected into the analytical instrument and separated and detected using specific chromatographic and mass spectrometric conditions;

[0102] Data processing: Based on the signal output by the instrument, the content of the active ingredient is calculated by data processing software.

[0103] This embodiment first The square root operation is used to represent the "comprehensive" effect, especially when dealing with volatile data. The purpose of this calculation is to evaluate the drug effect under the unit active ingredient content, by dividing the i-th drug ingredient content YF i Dividing the recommended dose and its fluctuation by the combined value can give an index reflecting the drug efficiency. The higher this index is, the higher the efficiency of the drug's active ingredient is within the given dose fluctuation range. Calculation part The overall formula, which comprehensively evaluates the actual efficacy of a drug by subtracting the side effect index from the unit effective ingredient efficiency, aims to derive an indicator that accurately reflects the quality of the drug's efficacy and provides a basis for the hierarchical and classified management of drugs.

[0104] In this algorithm unit, the efficacy evaluation value of the i-th drug YWL i It not only considers the active ingredients and recommended doses of the drug, but also introduces the standard deviation of the dose to reflect the fluctuation of the dose, while deducting the impact of side effects, so as to more comprehensively and accurately evaluate the efficacy of the drug;

[0105] This algorithm unit can be based on the i-th drug efficacy evaluation value YWL i The size of the drug can be used to judge the efficacy of the drug, so that the selection of drugs is more scientific and reasonable. The efficacy evaluation value of the i-th drug YWL i A drug with a high value usually means better efficacy and fewer side effects, and can use the efficacy evaluation value YWL of the i-th drug i As one of the indicators for drug screening and optimization, the efficacy evaluation value YWL of the i-th drug is improved by adjusting the active ingredient content and recommended dose of the drug. i value, thereby improving the efficacy and safety of drugs.

[0106] See also Figures 1-4, the calculation formula for the drug classification level division unit is as follows:

[0107] ;

[0108] in:

[0109] DJ i is the classification grade index of the i-th drug;

[0110] ZB i is the treatment cost of the i-th drug;

[0111] YWL max The maximum value for drug efficacy evaluation, YWL max Reflect all drugs for treating coronary heart disease in cardiology, calculate and output the efficacy evaluation value YWL of the i-th drug i The maximum value of

[0112] The result of the division represents the recommended dose required per unit active ingredient, that is, the dosage efficiency of the drug.

[0113] This embodiment first In the calculation part, The result of the division represents the recommended dose required per unit active ingredient, that is, the dose efficiency of the drug. This result is divided with the treatment cost ZB of the i-th drug. i Adding together is a comprehensive consideration of drug dosage efficiency and cost. The calculation part combines two important factors: drug treatment cost and dose efficiency, and evaluates the drug from the perspective of economy and drug utilization, and then compares it with the efficacy evaluation value YWL of the i-th drug. i Multiplication combines the drug efficacy evaluation index with this comprehensive consideration to obtain a drug classification grade index that takes into account both efficacy and cost and dosage efficiency;

[0114] The calculation part considers the efficacy evaluation value YWL of the i-th drug i Maximum YWL for drug efficacy evaluation max Ratio to the cost of treatment with drug ZB i The impact of The calculation part takes into account the influence of the position of the drug in the overall efficacy level on the cost from the perspective of the relativity of drug efficacy. After subtracting this influence, the influence between the cost and efficacy of the i-th drug can be combined to calculate the classification grade index DJ of the i-th drug. i ;

[0115] In this algorithm unit, the classification index DJ of the i-th drug iBy comprehensively considering multiple factors such as drug efficacy, treatment cost, and the ratio of active ingredients to recommended doses, drugs are divided into different grades, which helps to more accurately match patient needs when selecting drugs. The i-th drug classification grade index DJ i A drug with a high DR-I usually performs better in terms of efficacy, treatment cost, and safety, and therefore can serve as an important basis for optimizing drug selection;

[0116] This algorithm unit gives priority to the classification index DJ of the i-th drug i High-efficiency drugs can reduce patients' medical costs and improve the utilization efficiency of medical resources while ensuring the treatment effect.

[0117] See also Figures 1-4 , the calculation formula for guiding the drug library adjustment unit is as follows:

[0118] ;

[0119] T=(ZB avg / ZB i )×a;

[0120] in:

[0121] DT i Optimize the adjustment coefficient for the i-th drug;

[0122] YF avg is the average content of the drug component, YF avg Reflects the average content of ingredients in all drugs used to treat coronary heart disease in cardiology;

[0123] ZB avg is the average drug treatment cost, ZB avg Reflects the average cost of all drugs used to treat coronary heart disease in cardiology;

[0124] T is the adjustment factor, which is used to adjust the treatment cost to optimize the adjustment coefficient DT of the i-th drug i the impact of;

[0125] a is the adjustment coefficient, and its value range is {0.2-0.8}, which is calculated based on the last time all drugs are optimized for the adjustment coefficient DT of the i-th drug i , and arrange them in order of high and low to match the value range {0.2-0.8}:

[0126] The value of the i-th drug with a high ranking tends to be 0.8;

[0127] The value of the i-th drug with a low ranking tends to be 0.2.

[0128] This embodiment first In the calculation part, under the square root This result was also used to emphasize the effect of dose fluctuation on drug effect. The difference between the unit active ingredient and the average active ingredient is used to optimize the adjustment coefficient DT of the i-th drug, taking into account the combined effect of the dose and its fluctuation. i The higher the ratio, the greater the room for optimization of the active ingredient content of the drug relative to the average level within the dosage fluctuation range. The calculation part starts from the differences in drug ingredients and dosage factors, provides a basis for judging the optimization and adjustment needs of drugs in the drug library, and then The result of the calculation part is consistent with the classification index DJ of the i-th drug i Multiplication and addition are to convert the i-th drug classification index DJ i Combined with the optimization adjustment demand based on dosage fluctuation and active ingredient difference, a coefficient that comprehensively reflects the optimization adjustment demand of drugs is obtained. The higher this coefficient is, the greater the optimization adjustment demand of the drug in the drug library is. It is worth noting that the DJ index of the i-th drug classification level is i Multiplication and addition can ensure that when calculating the drug optimization adjustment coefficient, the comprehensive characteristics of the drug itself are taken into account, that is, the classification grade index DJ of the i-th drug is used. i Reflected, and considering the differences in ingredient content and treatment cost compared with other drugs, that is The calculation part provides an accurate basis for the hierarchical classification management and dynamic adjustment of the drug library. Removing the addition part will destroy this logical integrity, making the calculation results unable to accurately reflect the actual status of the drug in the drug library and the required adjustment direction and degree;

[0129] In the calculation part, the cost of drug treatment ZB i Divide by The sum of represents the comprehensive consideration of the drug treatment cost relative to the average cost and the adjustment factor T, and this result is combined with the classification index DJ of the i-th drug i Multiplication is to convert the i-th drug classification index DJ i Combined with this need for optimal adjustment based on treatment costs and regulatory factors, The calculation part is based on the perspective of drug cost, and the introduction of the adjustment factor T is to adjust the treatment cost to optimize the adjustment coefficient DT of the i-th drug i The degree of impact of the drug treatment cost is more consistent with the needs of actual applications, and this calculation part is intended to reflect the need for optimal adjustment of drug treatment costs;

[0130] In this algorithm unit, the optimization adjustment coefficient DT of the i-th drug i It can be used as one of the important indicators for the hierarchical classification management of the drug library, and the adjustment coefficient DT can be optimized by sorting the i-th drug. i The value can identify drugs that need to be optimized and adjusted, thereby guiding the management and update of the drug library. When multiple drugs are used in combination, the adjustment coefficient DT of the i-th drug of different drugs can be optimized by comparing them. i C value, optimize drug combination, improve overall therapeutic effect and safety, among which, for the i-th drug, the adjustment coefficient DT is optimized i For drugs with low values, their optimization adjustment coefficient DT of the i-th drug can be improved by developing new drugs and improving existing drugs. i value, thereby promoting the continuous innovation and development of drugs.

[0131] See also Figures 1-4 , guiding the drug library adjustment unit to optimize the adjustment coefficient DT of the i-th drug of all drugs i The calculation output is performed and the values ​​are classified from left to right according to their height. Based on the setting that the low values ​​below the median need to be adjusted, the i-th drug is analyzed one by one. The specific analysis is as follows:

[0132] If the i-th drug is among all the drugs, its i-th drug efficacy evaluation value YWL i If the value is low, it means that the efficacy of the i-th drug is insufficient, and the composition and dosage of the i-th drug should be optimized and adjusted according to the dosage fluctuation and side effects;

[0133] If the i-th drug is among all the drugs, its i-th drug classification index DJ i If it remains at a low value for a long time, it means that the treatment cost of the drug is high and the efficacy is poor, and it is necessary to adjust the drug classification and find alternative drugs.

[0134] This algorithm unit can continuously improve the efficacy evaluation value YWL of the i-th drug by continuously adjusting and optimizing the active ingredient content and recommended dosage parameters of the drug. i , thereby improving the efficacy and safety of drugs, and the formed circular influence mechanism makes the management of the drug library more dynamic and flexible, and can timely adjust and optimize drug combinations according to actual needs, thereby improving the efficiency and effectiveness of drug management. In addition, by continuously optimizing the management and combination of drug libraries, it can improve the overall medical quality, reduce patients' medical risks and economic burdens, and enhance the satisfaction and sustainability of medical services;

[0135] Specifically, by classifying and grading the drugs, the optimal adjustment coefficient DT of the i-th drug of each drug is output. i, which can more quickly and accurately select the right medicine for the patient. This classification and grading method makes the drug selection process more systematic and standardized, reducing the subjectivity and uncertainty of doctors when choosing drugs. At the same time, focusing on and optimizing drugs with low median values ​​can further improve the pertinence and effectiveness of drug selection;

[0136] For the efficacy evaluation value of the i-th drug YWL i Low-dose drugs can significantly improve their efficacy by increasing the active ingredient content and adjusting the recommended dosage. This optimization strategy not only improves the therapeutic effect of the drug, but also reduces treatment failure and patient suffering caused by poor drug efficacy. At the same time, it also provides new ideas and methods for drug research and development, helping to promote progress and innovation in drug research and development.

[0137] For the long-term i-th drug classification index DJ i Low-cost drugs, that is, drugs with high treatment costs and poor efficacy, can be used to reduce costs and improve efficacy by finding alternative drugs to alleviate the financial burden on patients. This substitution strategy not only helps to achieve the rational use of drugs, but also promotes the optimal allocation of medical resources. At the same time, it also provides a reference basis for the formulation of drug policies and helps promote the reform and improvement of the medical system.

[0138] In summary, optimizing drug classification and grading and comprehensively applying the mentioned strategies have significant beneficial effects on the selection and treatment effects of drugs for the treatment of coronary heart disease in cardiology. The implementation of this strategy not only improves the efficiency and efficacy of drug selection, but also reduces treatment costs, improves patient satisfaction and safety, and promotes the advancement and innovation of medical technology. Therefore, this strategy deserves to be widely promoted and applied in the medical field.

[0139] For example 2, please refer to Figures 1-4 The grading and classification module, in conjunction with the data collection and processing module, needs to regularly update the side effects of all drugs to reflect the adverse reaction feedback of patients in the current period. This usually includes the following steps:

[0140] Data collection: Collect the number of adverse reactions F experienced by patients while taking the i-th drug, as well as the total number of people n who took the i-th drug in the current period;

[0141] Data analysis: Statistics were collected on the number of adverse reactions F and the total number of people n, and the FZ i =F / n calculation formula, calculate the incidence of all kinds of adverse drug reactions;

[0142] Index update: According to the analysis and calculation results, FZ i Updated to reflect current adverse reaction information.

[0143] In this embodiment, the side effect index FZ of the i-th drug is updated regularly. i , which can ensure the accuracy and timeliness of drug safety assessment. With the continuous accumulation of new data, the understanding of drug side effects will be more in-depth, so that the risk of drugs can be assessed more accurately. The pharmacovigilance system is designed to monitor the safety issues of drugs during use and regularly update the i-th drug side effect index FZ i It helps to timely discover and report new and serious side effects, thereby promoting the improvement of the pharmacovigilance system;

[0144] For drugs under development or optimization, the side effect index FZ of the i-th drug is updated regularly i It can provide key safety information to help make more informed decisions and regularly update the side effect index FZ of the i-th drug i , medical institutions can more accurately assess the safety risks of different drugs, thereby optimizing the allocation of medical resources;

[0145] In summary, the side effect index FZ of the i-th drug i Regular updates have many beneficial effects, including improving the accuracy of drug safety assessments, promoting the improvement of pharmacovigilance systems, supporting drug research and development and optimization, enhancing patient confidence and compliance, and optimizing the allocation of medical resources. These beneficial effects together promote the safety and effectiveness of drug use.

[0146] Although the present invention is disclosed as above, the present invention is not limited thereto. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the scope defined by the claims.

Claims

1. A hierarchical classification management system based on the cardiology department's coronary heart disease drug library includes a data collection and processing module, a hierarchical classification module, a data analysis module, and an analysis visualization module. It is characterized by: The data collection and processing module collects and classifies the classified data of all kinds of drugs used to treat coronary heart disease in the current period of time, and transmits the data to the grading and classification module; The classification module calculates and outputs the i-th drug efficacy evaluation value YWL of all drugs in turn. i , the i-th drug classification index DJ i , optimization adjustment coefficient DT of the i-th drug i ; The data analysis module calculates and outputs the optimal adjustment coefficient DT of the i-th drug for all drugs i Arrange them and optimize the hierarchical classification management of the i-th drug with a low value below the median; The analysis visualization module displays the results of all drug arrangements and optimization adjustments; The grading and classification module includes a unit for judging the efficacy of drugs, a unit for classifying drugs, and a unit for guiding the adjustment of drug libraries. In calculating the efficacy evaluation value YWL of the i-th drug i This includes regular updates of data input on patient adverse reaction feedback over the current period.

2. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 1 is characterized by: The grading and classification module cooperates with the data collection and processing module to regularly update the side effects of all drugs to reflect the adverse reaction feedback of patients in the current period, including the following steps: Data collection: Collect the number of adverse reactions F experienced by patients while taking the i-th drug, as well as the total number of people n who took the i-th drug in the current period; Data analysis: Statistics were collected on the number of adverse reactions F and the total number of people n, and the FZ i =F / n calculation formula, calculate the incidence of all kinds of adverse drug reactions; Index update: According to the analysis and calculation results, FZ i Updated to reflect current adverse reaction information.

3. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 2 is characterized by: The calculation formula for the drug efficacy judgment unit is as follows: ； in: YWL i is the efficacy evaluation value of the i-th drug; YF i is the content of the i-th drug component, YF i Reflects the content of the active ingredient used for therapeutic effects in the i-th drug; J i is the dose of the i-th drug, J i Reflects the recommended single-dose dosage of the i-th drug as marked on the medicine box; JB i is the standard deviation of the dose of the i-th drug, JB i Reflects the degree of fluctuation of dose in actual quality; FZ i is the side effect index of the i-th drug; The dose of drug i in i Fixed, the standard deviation of the dose of drug i, JB i There are fluctuations, and The calculation of the standard deviation JB of the dose of the i-th drug is i After the fluctuation effect, the dose of the i-th drug J i and the weakening of.

4. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 3 is characterized by: The calculation formula of the drug classification level division unit is as follows: ； in: DJ i is the classification grade index of the i-th drug; ZB i is the treatment cost of the i-th drug; YWL max The maximum value for drug efficacy evaluation, YWL max Reflect all drugs for treating coronary heart disease in cardiology, calculate and output the efficacy evaluation value YWL of the i-th drug i The maximum value of The result of the division represents the recommended dose required per unit active ingredient, that is, the dosage efficiency of the drug.

5. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 4 is characterized by: The calculation formula of the guiding drug library adjustment unit is as follows: ； T=(ZB avg / ZB i )×a; in: DT i Optimize the adjustment coefficient for the i-th drug; YF avg is the average content of the drug component, YF avg Reflects the average content of ingredients in all drugs used to treat coronary heart disease in cardiology; ZB avg is the average drug treatment cost, ZB avg Reflects the average cost of all drugs used to treat coronary heart disease in cardiology; T is the adjustment factor, which is used to adjust the treatment cost to optimize the adjustment coefficient DT of the i-th drug i the impact of; a is the adjustment coefficient, and its value range is {0.2-0.8}, which is calculated based on the last time all drugs are optimized for the adjustment coefficient DT of the i-th drug i , and arrange them in order of high and low to match the value range {0.2-0.8}: The value of the i-th drug with a high ranking tends to be 0.8; The value of the i-th drug with a low ranking tends to be 0.

2.

6. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 5 is characterized by: The guiding drug library adjustment unit optimizes the adjustment coefficient DT of the i-th drug of all drugs i The calculation output is performed and the values ​​are classified from left to right according to their height. Based on the setting that the low values ​​below the median need to be adjusted, the i-th drug is analyzed one by one. The analysis is as follows: If the i-th drug is among all the drugs, its i-th drug efficacy evaluation value YWL i If the value is low, it means that the efficacy of the i-th drug is insufficient, and the composition and dosage of the i-th drug should be optimized and adjusted according to the dosage fluctuation and side effects; If the i-th drug is among all the drugs, its i-th drug classification index DJ i If it remains at a low value for a long time, it means that the treatment cost of the drug is high and the efficacy is poor, and it is necessary to adjust the drug classification and find alternative drugs.

7. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 3 is characterized by: The standard deviation of the dose of the i-th drug JB i The calculation formula is as follows: ； ； in: J k is the drug dosage of the kth individual, J k Reflects the actual single dose of the i-th drug taken during the current period; J avg is the average drug dose, J avg Reflects the average degree of single and actual dosage of the i-th drug taken by n patients in the current period.

8. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 3 is characterized by: The content of the i-th medicinal ingredient YF i The determination is carried out using analytical instruments such as high performance liquid chromatography, gas chromatography, and mass spectrometry. These devices accurately measure the concentration of specific chemical components in the drug and obtain the content of the active ingredient. The specific implementation method is as follows: Sample preparation: extracting the active ingredient from the i-th drug preparation, the extraction including the steps of dissolution, filtration, and concentration; Instrumental analysis: The extracted and processed sample of the i-th drug preparation is injected into the analytical instrument and separated and detected using specific chromatographic and mass spectrometric conditions; Data processing: Based on the signal output by the instrument, the content of the active ingredient is calculated by data processing software.

9. The hierarchical classification management system based on the cardiology coronary heart disease drug library according to claim 1 is characterized by: The equipment used by the data collection and processing module includes a database management system and network equipment; The equipment used in the grading and classification module includes computers, servers, and data processing software; The equipment used by the data analysis module includes data analysis software; The equipment used by the analysis and visualization module includes a display.

Images